Led · Series A · Apr 2026

Vivacta is developing next-generation in vivo CAR-T therapies, with its lead program GT801 focused on hematologic malignancies and autoimmune diseases. Early clinical data reported at ASH 2025 indicated promising safety and efficacy signals for GT801. The company plans to use new financing to advance GT801 clinical trials, pursue regulatory submission and approval, expand its research team and platform, and drive global expansion. Vivacta describes its investor base as a mix of global industrial capital and specialist biotech investors, and raised over US$50 million in its Series A and Series A+ financings. After the financing, representatives from Loyal Valley Capital and DC Global Ventures joined the board, signaling investor engagement in governance and strategy.

Participated · Series B · Feb 2026

Founded in 2023 and based in Beijing, Galaxea AI develops embodied intelligence systems centered on Vision‑Language‑Action (VLA) models and World Action Models. The company emphasizes a tightly integrated approach where VLA and World Action Models co‑evolve using massive real‑world datasets collected from open environments. Galaxea has open‑sourced three VLA models to date and contrasts its real‑data‑driven approach with competitors that rely primarily on simulation. The firm acknowledges challenges of high data collection difficulty, cost, and slower scalability inherent to its chosen data strategy. Following a nearly CNY1 billion Series B in February, Galaxea completed a nearly CNY2 billion Series B+ at a CNY200 billion valuation to fund further R&D, ecosystem expansion, and commercial deployment efforts.

Led · Equity · Jan 2026

Beijing-based Surgerii Robotics designs, manufactures, and markets laparoscopic surgical robotic systems and accessories, spearheaded by its flagship Shurui single-port endoscopic surgical robot (SR-ENS-600). The system employs snake-like, tele-operated instruments based on a Dual Continuum Mechanism developed at Shanghai Jiao Tong University, allowing complex procedures through one small incision. Shurui secured China NMPA clearance in June 2023 and CE marking in August 2025, becoming the first single-port robot approved for pediatric use and the second ever CE-certified platform after Intuitive’s da Vinci SP. Clinically, the company has partnered with more than 70 Grade A tertiary hospitals in China, supported over 3,000 surgeries, and enabled nearly 50 distinct procedures worldwide, developing 80+ new surgical techniques. Surgerii has also launched a European Clinical Excellence Center with IRCAD to drive adoption in high-end European markets. Future plans include accelerating international commercialization, expanding clinical applications, and developing next-generation energy instruments and other products. The recent $100 million financing fortifies its cash position to scale production, deepen domestic penetration, and enter additional global markets.

Participated · Series E · Feb 2024

Founded in 2017 and headquartered in Suzhou, 信诺维 is a platform-oriented innovative drug company focused on addressing major unmet clinical needs. The company has built proprietary platforms in targeted therapy, anti-infection agents and PROTACs and has formed leading global pipelines including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors and next-generation ADCs. It currently has nine products in domestic and international clinical development, with two programs in Phase III and several in Phase I–II. Lead anti-infective XNW4107 is in a global multi-center pivotal Phase III trial targeting carbapenem-resistant pathogens; XNW3009 (urate-lowering) is in Phase III and showed superior urate-lowering vs comparators in randomized double-blind trials. Oncology programs include EZH2 inhibitor XNW5004 (Phase II) with a collaboration with MSD and combination trials with a “K” drug, and next-gen ADCs XNW27/XNW28 in Phase I. The company has completed multiple out-licenses with aggregate amounts described as 数十亿美元 and has raised cumulative financing exceeding ¥2 billion RMB to date. 信诺维 is an innovative pharmaceutical company founded in 2017 that focuses on addressing major unmet clinical needs and holds global intellectual property. Headquartered in Suzhou, the company has branches in Beijing, Shanghai, Australia and Boston and has received regional awards and recognitions. Its pipeline targets both Best‑in‑Class and First‑in‑Class programs across oncology, anti‑infectives, autoimmune and metabolic diseases, with five products in clinical stages and three in IND‑enabling stages. In December 2020 the company completed a several‑hundred‑million‑RMB Pre‑IPO financing led by Haishong Capital with participation from China Development Capital, Jiuyou Capital, Fengyi Yuanda Capital, Agricultural Bank International and Deguang Capital. Proceeds will be used to advance domestic and international clinical trials and to construct a new drug production base. The company has built a comprehensive team of industry professionals and expects the new manufacturing base to accelerate product commercialization and attract additional biopharma talent to the region.

Led · Equity · Aug 2023

Founded in 2018 by Peking University alumni Zhang Linfeng and Sun Weijie, DP Technology develops a suite of artificial-intelligence tools aimed at speeding up scientific discovery across multiple disciplines. Its flagship offerings include Particle Universe for molecular simulations, Uni-Lab for laboratory operations, Bohrium as a cloud research hub and Hermite for computer-aided drug design. Additional products such as RiDYMO (targeting “undruggable” biology), Piloteye (battery design), SciMaster (a general scientific AI agent) and Lebesgue Intelligent Computing (network traffic control) broaden its reach. The company’s technology is reportedly used by more than 1,000 universities and research organizations and 150 corporate clients, including PetroChina and BYD Auto. Co-founder Zhang Linfeng, an ACM Gordon Bell Prize winner, positions the firm’s mission as building “AI scientists” that can automate discovery. With its newly secured Series C funding, DP Technology plans to expand hiring and accelerate R&D on additional AI-driven scientific tools. The startup has now raised $114 million to support these ambitions.